Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is ...
Medtronic (NYSE:MDT) today announced new milestones for its Affera family of technologies, including FDA breakthrough device ...
CHICAGO, IL—When patients stop taking oral anticoagulation (OAC) after they’ve been free of atrial fibrillation (AF) ...
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated ...
Boston Scientific (NYSE:BSX) today shared new clinical findings supporting its wide-ranging electrophysiology (EP) portfolio.
Pulse Biosciences is positioning its nanosecond PFA technology as a game-changer in the competitive atrial fibrillation ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field ...
Demonstrating that the best solution is not always a multistage approach, a new trial showed catheter ablation is superior to a combination of antiarrhythmic drugs and lifestyle changes — weight loss, ...
Compared with medical therapy, rhythm control with catheter ablation is associated with lower risk of ischemic stroke after 30 days, as well as less mortality and heart failure (HF) hospitalization, ...
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the U.S.
Every year millions of people around the world are diagnosed with heart failure, a chronic, progressive condition where the heart is unable to pump enough oxygenated blood throughout the body.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results